Literature DB >> 11498528

CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

P Hasbak1, A Sams, S Schifter, J Longmore, L Edvinsson.   

Abstract

1. Calcitonin gene-related peptide (CGRP), amylin and adrenomedullin (AM) belong to the same family of peptides. Accumulating evidence indicate that the calcitonin (CT) receptor, the CT receptor-like receptor (CRLR) and receptor-activity-modifying proteins (RAMPs) form the basis of all the receptors in this family of peptides. 2. Using reverse transcriptase - polymerase chain reaction the presence of mRNA sequences encoding the CRLR, RAMP1 and RAMP2 were demonstrated in porcine left anterior descending (LAD) coronary arteries, whereas porcine calcitonin (CT) receptor mRNA was not present. The partial porcine mRNA sequences shared 82 - 92% nucleotide identity with human sequences. 3. The human peptides alphaCGRP, betaCGRP, AM and amylin induced relaxation with pEC(50) values of 8.1, 8.1, 6.7 and 6.1 M respectively. 4. The antagonistic properties of a novel non-peptide CGRP antagonist 'Compound 1' (WO98/11128), betaCGRP(8 - 37) and the proposed AM receptor antagonist AM(22 - 52) were compared to the well-known CGRP(1) receptor antagonist alphaCGRP(8 - 37). 5. The alphaCGRP(8 - 37) and betaCGRP(8 - 37) induced concentration-dependent (10(-7) - 10(-5) M) rightward shift of both the alphaCGRP and betaCGRP concentration-response curves. betaCGRP(8 - 37) (10(-6) M) had the same effect as alphaCGRP(8 - 37) (10(-6) M), but with less potent rightward shift of the concentration-response curves for alphaCGRP, AM and amylin. 6. Preincubation with 'Compound 1' (10(-7) - 10(-5) M) and AM(22 - 52) (10(-6) M) had no significant antagonistic effect. 7. In conclusion, the building blocks forming CGRP and AM receptors were present in the porcine LAD, whereas those of the amylin receptor were not. alphaCGRP, betaCGRP, AM and amylin mediated vasorelaxation via the CGRP receptors. No functional response was detected to adrenomedullin via the adrenomedullin receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498528      PMCID: PMC1621165          DOI: 10.1038/sj.bjp.0704210

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  Decreased adrenomedullin production in the coronary circulation of patients with coronary artery disease.

Authors:  Y Hojo; U Ikeda; T A Katsuki; K Shimada
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 2.  RAMPs: accessory proteins for seven transmembrane domain receptors.

Authors:  S M Foord; F H Marshall
Journal:  Trends Pharmacol Sci       Date:  1999-05       Impact factor: 14.819

3.  Plasma CGRP in acute myocardial infarction.

Authors:  J Mair; P Lechleitner; T Längle; C Wiedermann; F Dienstl; A Saria
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

4.  Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product.

Authors:  G Christopoulos; K J Perry; M Morfis; N Tilakaratne; Y Gao; N J Fraser; M J Main; S M Foord; P M Sexton
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

5.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

6.  A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1.

Authors:  N Bühlmann; K Leuthäuser; R Muff; J A Fischer; W Born
Journal:  Endocrinology       Date:  1999-06       Impact factor: 4.736

Review 7.  The molecular pharmacology of CGRP and related peptide receptor subtypes.

Authors:  C Juaneda; Y Dumont; R Quirion
Journal:  Trends Pharmacol Sci       Date:  2000-11       Impact factor: 14.819

Review 8.  Clinical perspectives of calcitonin gene related peptide pharmacology.

Authors:  G Feuerstein; R Willette; N Aiyar
Journal:  Can J Physiol Pharmacol       Date:  1995-07       Impact factor: 2.273

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Recent advances in our understanding of peptide hormone receptors and RAMPS.

Authors:  P M Sexton
Journal:  Curr Opin Drug Discov Devel       Date:  1999-09
View more
  6 in total

1.  Increased alphaCGRP potency and CGRP-receptor antagonist affinity in isolated hypoxic porcine intramyocardial arteries.

Authors:  Philip Hasbak; Karen Eskesen; Søren Schifter; Lars Edvinsson
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 2.  CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors?

Authors:  C S Walker; D L Hay
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 3.  Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.

Authors:  Eric L Moore; Christopher A Salvatore
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

5.  Differential effect of amylin on endothelial-dependent vasodilation in mesenteric arteries from control and insulin resistant rats.

Authors:  Mariam El Assar; Javier Angulo; Marta Santos-Ruiz; Paola Moreno; Anna Novials; María Luisa Villanueva-Peñacarrillo; Leocadio Rodríguez-Mañas
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

6.  Sensory Neuropeptides and their Receptors Participate in Mechano-Regulation of Murine Macrophages.

Authors:  Dominique Muschter; Anna-Sophie Beiderbeck; Tanja Späth; Christian Kirschneck; Agnes Schröder; Susanne Grässel
Journal:  Int J Mol Sci       Date:  2019-01-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.